Recommendations for imaging tumor response in neurofibromatosis clinical trials.

Eva Dombi, Simone L. Ardern-Holmes, Dusica Babovic-Vuksanovic, Fred G. Barker, Steve Connor, D. Gareth Evans, Michael J. Fisher, Stephane Goutagny, Gordon J. Harris, Diego Jaramillo, Matthias A. Karajannis, Bruce R. Korf, Victor Mautner, Scott R. Plotkin, Tina Y. Poussaint, Kent Robertson, Chie-Schin Shih, Brigitte C. Widemann, International Collaboration REiNS International Collaboration

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors have become available. Due to differences in disease manifestations and the natural history of NF-related tumors, response criteria used for solid cancers (1-dimensional/RECIST [Response Evaluation Criteria in Solid Tumors] and bidimensional/World Health Organization) have limited applicability. No standardized response criteria for benign NF tumors exist. The goal of the Tumor Measurement Working Group of the REiNS (Response Evaluation in Neurofibromatosis and Schwannomatosis) committee is to propose consensus guidelines for the evaluation of imaging response in clinical trials for NF tumors. Currently used imaging endpoints, designs of NF clinical trials, and knowledge of the natural history of NF-related tumors, in particular PN and VS, were reviewed. Consensus recommendations for response evaluation for future studies were developed based on this review and the expertise of group members. MRI with volumetric analysis is recommended to sensitively and reproducibly evaluate changes in tumor size in clinical trials. Volumetric analysis requires adherence to specific imaging recommendations. A 20% volume change was chosen to indicate a decrease or increase in tumor size. Use of these criteria in future trials will enable meaningful comparison of results across studies. The proposed imaging response evaluation guidelines, along with validated clinical outcome measures, will maximize the ability to identify potentially active agents for patients with NF and benign tumors.

Original languageEnglish (US)
JournalNeurology
Volume81
Issue number21 Suppl 1
StatePublished - Nov 19 2013
Externally publishedYes

Fingerprint

Neurofibromatoses
Clinical Trials
Neoplasms
Plexiform Neurofibroma
Acoustic Neuroma
Imaging
Guidelines
Evaluation
Proxy
Outcome Assessment (Health Care)
Morbidity

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)
  • Medicine(all)

Cite this

Dombi, E., Ardern-Holmes, S. L., Babovic-Vuksanovic, D., Barker, F. G., Connor, S., Evans, D. G., ... REiNS International Collaboration, I. C. (2013). Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology, 81(21 Suppl 1).

Recommendations for imaging tumor response in neurofibromatosis clinical trials. / Dombi, Eva; Ardern-Holmes, Simone L.; Babovic-Vuksanovic, Dusica; Barker, Fred G.; Connor, Steve; Evans, D. Gareth; Fisher, Michael J.; Goutagny, Stephane; Harris, Gordon J.; Jaramillo, Diego; Karajannis, Matthias A.; Korf, Bruce R.; Mautner, Victor; Plotkin, Scott R.; Poussaint, Tina Y.; Robertson, Kent; Shih, Chie-Schin; Widemann, Brigitte C.; REiNS International Collaboration, International Collaboration.

In: Neurology, Vol. 81, No. 21 Suppl 1, 19.11.2013.

Research output: Contribution to journalArticle

Dombi, E, Ardern-Holmes, SL, Babovic-Vuksanovic, D, Barker, FG, Connor, S, Evans, DG, Fisher, MJ, Goutagny, S, Harris, GJ, Jaramillo, D, Karajannis, MA, Korf, BR, Mautner, V, Plotkin, SR, Poussaint, TY, Robertson, K, Shih, C-S, Widemann, BC & REiNS International Collaboration, IC 2013, 'Recommendations for imaging tumor response in neurofibromatosis clinical trials.', Neurology, vol. 81, no. 21 Suppl 1.
Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013 Nov 19;81(21 Suppl 1).
Dombi, Eva ; Ardern-Holmes, Simone L. ; Babovic-Vuksanovic, Dusica ; Barker, Fred G. ; Connor, Steve ; Evans, D. Gareth ; Fisher, Michael J. ; Goutagny, Stephane ; Harris, Gordon J. ; Jaramillo, Diego ; Karajannis, Matthias A. ; Korf, Bruce R. ; Mautner, Victor ; Plotkin, Scott R. ; Poussaint, Tina Y. ; Robertson, Kent ; Shih, Chie-Schin ; Widemann, Brigitte C. ; REiNS International Collaboration, International Collaboration. / Recommendations for imaging tumor response in neurofibromatosis clinical trials. In: Neurology. 2013 ; Vol. 81, No. 21 Suppl 1.
@article{267c85264fa443ba990cef7b5fd636e7,
title = "Recommendations for imaging tumor response in neurofibromatosis clinical trials.",
abstract = "Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors have become available. Due to differences in disease manifestations and the natural history of NF-related tumors, response criteria used for solid cancers (1-dimensional/RECIST [Response Evaluation Criteria in Solid Tumors] and bidimensional/World Health Organization) have limited applicability. No standardized response criteria for benign NF tumors exist. The goal of the Tumor Measurement Working Group of the REiNS (Response Evaluation in Neurofibromatosis and Schwannomatosis) committee is to propose consensus guidelines for the evaluation of imaging response in clinical trials for NF tumors. Currently used imaging endpoints, designs of NF clinical trials, and knowledge of the natural history of NF-related tumors, in particular PN and VS, were reviewed. Consensus recommendations for response evaluation for future studies were developed based on this review and the expertise of group members. MRI with volumetric analysis is recommended to sensitively and reproducibly evaluate changes in tumor size in clinical trials. Volumetric analysis requires adherence to specific imaging recommendations. A 20{\%} volume change was chosen to indicate a decrease or increase in tumor size. Use of these criteria in future trials will enable meaningful comparison of results across studies. The proposed imaging response evaluation guidelines, along with validated clinical outcome measures, will maximize the ability to identify potentially active agents for patients with NF and benign tumors.",
author = "Eva Dombi and Ardern-Holmes, {Simone L.} and Dusica Babovic-Vuksanovic and Barker, {Fred G.} and Steve Connor and Evans, {D. Gareth} and Fisher, {Michael J.} and Stephane Goutagny and Harris, {Gordon J.} and Diego Jaramillo and Karajannis, {Matthias A.} and Korf, {Bruce R.} and Victor Mautner and Plotkin, {Scott R.} and Poussaint, {Tina Y.} and Kent Robertson and Chie-Schin Shih and Widemann, {Brigitte C.} and {REiNS International Collaboration}, {International Collaboration}",
year = "2013",
month = "11",
day = "19",
language = "English (US)",
volume = "81",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "21 Suppl 1",

}

TY - JOUR

T1 - Recommendations for imaging tumor response in neurofibromatosis clinical trials.

AU - Dombi, Eva

AU - Ardern-Holmes, Simone L.

AU - Babovic-Vuksanovic, Dusica

AU - Barker, Fred G.

AU - Connor, Steve

AU - Evans, D. Gareth

AU - Fisher, Michael J.

AU - Goutagny, Stephane

AU - Harris, Gordon J.

AU - Jaramillo, Diego

AU - Karajannis, Matthias A.

AU - Korf, Bruce R.

AU - Mautner, Victor

AU - Plotkin, Scott R.

AU - Poussaint, Tina Y.

AU - Robertson, Kent

AU - Shih, Chie-Schin

AU - Widemann, Brigitte C.

AU - REiNS International Collaboration, International Collaboration

PY - 2013/11/19

Y1 - 2013/11/19

N2 - Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors have become available. Due to differences in disease manifestations and the natural history of NF-related tumors, response criteria used for solid cancers (1-dimensional/RECIST [Response Evaluation Criteria in Solid Tumors] and bidimensional/World Health Organization) have limited applicability. No standardized response criteria for benign NF tumors exist. The goal of the Tumor Measurement Working Group of the REiNS (Response Evaluation in Neurofibromatosis and Schwannomatosis) committee is to propose consensus guidelines for the evaluation of imaging response in clinical trials for NF tumors. Currently used imaging endpoints, designs of NF clinical trials, and knowledge of the natural history of NF-related tumors, in particular PN and VS, were reviewed. Consensus recommendations for response evaluation for future studies were developed based on this review and the expertise of group members. MRI with volumetric analysis is recommended to sensitively and reproducibly evaluate changes in tumor size in clinical trials. Volumetric analysis requires adherence to specific imaging recommendations. A 20% volume change was chosen to indicate a decrease or increase in tumor size. Use of these criteria in future trials will enable meaningful comparison of results across studies. The proposed imaging response evaluation guidelines, along with validated clinical outcome measures, will maximize the ability to identify potentially active agents for patients with NF and benign tumors.

AB - Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors have become available. Due to differences in disease manifestations and the natural history of NF-related tumors, response criteria used for solid cancers (1-dimensional/RECIST [Response Evaluation Criteria in Solid Tumors] and bidimensional/World Health Organization) have limited applicability. No standardized response criteria for benign NF tumors exist. The goal of the Tumor Measurement Working Group of the REiNS (Response Evaluation in Neurofibromatosis and Schwannomatosis) committee is to propose consensus guidelines for the evaluation of imaging response in clinical trials for NF tumors. Currently used imaging endpoints, designs of NF clinical trials, and knowledge of the natural history of NF-related tumors, in particular PN and VS, were reviewed. Consensus recommendations for response evaluation for future studies were developed based on this review and the expertise of group members. MRI with volumetric analysis is recommended to sensitively and reproducibly evaluate changes in tumor size in clinical trials. Volumetric analysis requires adherence to specific imaging recommendations. A 20% volume change was chosen to indicate a decrease or increase in tumor size. Use of these criteria in future trials will enable meaningful comparison of results across studies. The proposed imaging response evaluation guidelines, along with validated clinical outcome measures, will maximize the ability to identify potentially active agents for patients with NF and benign tumors.

UR - http://www.scopus.com/inward/record.url?scp=84892469825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892469825&partnerID=8YFLogxK

M3 - Article

C2 - 24249804

AN - SCOPUS:84892469825

VL - 81

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 21 Suppl 1

ER -